目的:探討基層醫院前列腺增生并膀胱結石的微創治療方法。方法:聯合經尿道等離子雙極電切與恥骨上小切口治41例前列腺增生癥并膀胱結石。結果:手術時間40~110min, 平均55min,術后3d拔造瘺管, 第5~6天拔除尿管,排尿通暢, 無電切綜合征(TURS)、大出血等并發癥,住院時間7±1.5天。數字疼痛評分0~6,平均3.5。結論：等離子體雙極電切結合恥骨上小切口是治療前列腺增生并膀胱結石的一種快速、安全有效、微創的手術方法,值得在基層醫院推廣。
ObjectiveTo systematically review the interventional effects of Simiao Yong'an decoction on atherosclerosis animal models.MethodsDatabase including CNKI, WanFang Data, VIP, PubMed, The Cochrane Library, and Web of Science were searched to collect animal experiments on atherosclerosis model intervention by Simiao Yong’an decoction from inception to October 2020. Two reviewers independently screened the literature, extracted data, and used the SYRCLE animal experiment bias risk assessment tool to evaluate risk bias of included studies, and then used RevMan 5.4.1 software for meta-analysis.ResultsA total of 14 animal experiments were included. The results of meta-analysis showed that compared with the blank model group, the Simiao Yong’an decoction group could reduce the aortic plaque area (SMD=?2.04, 95%CI ?3.35 to ?0.74), the ratio of aortic plaque to lumen area (SMD=?1.72, 95%CI ?2.48 to ?0.97), total cholesterol level (SMD=?0.97, 95 %CI ?1.72 to ?0.22), triglyceride level (SMD=?1.21, 95%CI ?1.82 to ?0.60), low-density lipoprotein cholesterol level (SMD=?1.82, 95%CI ?3.12 to ?1.53), tumor necrosis factor-α level (SMD=?3.36, 95%CI ?4.21 to ?2.52), monocyte chemotactic factor-1 level (SMD=?2.98, 95%CI ?4.60 to ?1.35) and C-reactive protein level (SMD=?0.60, 95%CI ?1.08 to ?0.11); however, in the high-density lipoprotein cholesterol level (SMD=0.66, 95%CI ?0.10 to 1.42) and the level of interleukin 1 (SMD=?1.41, 95%CI ?4.11 to 1.30), the differences were not statistically significant.ConclusionsThe existing evidence shows that the intervention of Simiao Yong’an decoction in the atherosclerosis model can reduce the aortic plaque area and the ratio of the aortic plaque to the lumen area, reduce total cholesterol, triglycerides, and low-density lipoprotein cholesterol levels, and reduce tumor necrosis factor-α, monocyte chemotactic factor-1, and C-reactive protein levels. Due to limited quality of included studies, more high quality studies are required to verify the above conclusions.